Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-92

Yes, it did put a solid foundation in Dryas…and as we have got that extra cash now, maybe we could put some of it to work on outsourcing some preclinical studies on Alzheimers or Parkinson’s disease, and take this little Piggy to market with multiple (1 Rare and Two Massive) indications.

As DrMT said in the AGM Presentation “27 odd billion when Amgen purchased Horizon Therapeutics and they had TWO rare disease programs in kidney disease”.

That line (blue underlined) is looking all important 13-4 years later… and it’s not like we have to worry about a majority of people in society fasting to achieve Autophagy.